Search Results - "Goldschmidt, Debbie"

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT by Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S, Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael

“…To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. Patients in…”
Get full text

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial by Bergman, Martin, Tundia, Namita, Martin, Naomi, Suboticki, Jessica L, Patel, Jayeshkumar, Goldschmidt, Debbie, Song, Yan, Wright, Grace C

“…In previous clinical trials, patients with active rheumatoid arthritis (RA) treated with upadacitinib (UPA) have improved patient-reported outcomes (PROs)…”
Get full text

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY by Strand, Vibeke, Tundia, Namita, Wells, Alvin, Buch, Maya H, Radominski, Sebastiao C, Camp, Heidi S, Friedman, Alan, Suboticki, Jessica L, Dunlap, Kendall, Goldschmidt, Debbie, Bergman, Martin

“…Abstract Objective To evaluate the effect of upadacitinib (UPA) monotherapy vs MTX on patient-reported outcomes (PROs) in patients with RA who were MTX-naïve…”
Get full text

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial by Bergman, Martin, Tundia, Namita, Martin, Naomi, Suboticki, Jessica L., Patel, Jayeshkumar, Goldschmidt, Debbie, Song, Yan, Wright, Grace C.

Get full text

Correction: Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States by Jain, Rakesh, Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Finkbeiner, Stacy, Leo, Sam

Get full text

Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States by Jain, Rakesh, Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Finkbeiner, Stacy, Leo, Sam

“…Background Tardive dyskinesia (TD) has a multidimensional impact on patients with TD and, as importantly, their caregivers. An online survey was developed and…”
Get full text

An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia by Ayyagari, Rajeev, Goldschmidt, Debbie, Mu, Fan, Caroff, Stanley N, Carroll, Benjamin

“…Antipsychotic medications may cause tardive dyskinesia (TD), an often-irreversible movement disorder characterized by involuntary movements that are typically…”
Get full text

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT by Strand, Vibeke, Pope, Janet, Tundia, Namita, Friedman, Alan, Camp, Heidi S, Pangan, Aileen, Ganguli, Arijit, Fuldeore, Mahesh, Goldschmidt, Debbie, Schiff, Michael

“…An amendment to this paper has been published and can be accessed via the original article…”
Get full text

Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study by Oladapo, Abiola, Kolodny, Scott, Vredenburg, Michael, Swallow, Elyse, Goldschmidt, Debbie, Sarathy, Kirthana, Lopez, Priscilla, Maitland, Hillary, Yee, John

“…Background: Thrombopoietin-receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), a disorder characterized by prolonged low platelet…”
Get full text

Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States by Jain, Rakesh, Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Finkbeiner, Stacy, Leo, Sam

“…To assess the physical, psychological, social, and professional impact of tardive dyskinesia (TD) on patients in the United States. An online survey (April…”
Get full text

Real-World Effectiveness and Safety of Deutetrabenazine in Combination with Antipsychotic Drugs in Patients With Chorea Associated With Huntington Disease (P2-11.010) by Claassen, Daniel, Romdhani, Hela, Ayyagari, Rajeev, Goldschmidt, Debbie, Moroz, Sarah, Hernandez, Adreanna, Chaijale, Nayla, Leo, Sam

“…Abstract only…”
Get full text

Trends over Time in Overall Survival of Patients with Multiple Myeloma By Race/Ethnicity and By Comorbidity Status: A Surveillance, Epidemiology, and End Results (SEER)-Medicare Analysis by Anwer, Faiz, Goldschmidt, Debbie, Tang, Wenxi, Steffen, David R., Yilma, Binyam, Slaff, Samantha

Get full text

Direct health care costs associated with COVID-19 in the United States by DeMartino, Jessica K, Swallow, Elyse, Goldschmidt, Debbie, Yang, Karen, Viola, Marta, Radtke, Tyler, Kirson, Noam

Get full text

Defining Utility Values for Chorea Health States in Patients With Huntington’s Disease (4360) by Claassen, Daniel O., Goldschmidt, Debbie, Zhou, Mo, Leo, Sam, Ribalov, Rinat, Ayyagari, Rajeev

“…Abstract only…”
Get full text

Defining utility values for patients with tardive dyskinesia by Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Ribalov, Rinat, Caroff, Stanley N., Leo, Sam

“…To measure health state preferences and estimate utility values for tardive dyskinesia (TD) from the perspective of the US general population, accounting for…”
Get full text

Real-World Treatment Patterns and Outcomes in Patients with Immune Thrombocytopenia Treated with Avatrombopag in the United States: Real-AVA 2.0 Study Design by Nagalla, Srikanth, Chaturvedi, Shruti, Levy, Moshe, Kolodny, Scott, Oladapo, Abiola, Bernheisel, Chelsea, Jamieson, Brian, Goldschmidt, Debbie, Swallow, Elyse, Greatsinger, Ali, Vredenburg, Michael

“…Background: Thrombopoietin-receptor agonists (TPO-RAs) are used in the treatment of chronic immune thrombocytopenia (ITP), a disorder characterized by…”
Get full text

Avatrombopag Treatment Response in Patients with Immune Thrombocytopenia: A Real-World Evidence Study by Oladapo, Abiola, Kolodny, Scott, Vredenburg, Michael, Jamieson, Brian, Swallow, Elyse, Goldschmidt, Debbie, Zichlin, Miriam L., Davidson, Mikhail, Yu, Louise, Yee, John

Get full text

Real-World Demographic and Clinical Characteristics of Patients Initiating Avatrombopag in the US: The Real-AVA Study by Kolodny, Scott, Oladapo, Abiola, Vredenburg, Michael, Jamieson, Brian, Swallow, Elyse, Goldschmidt, Debbie, Zichlin, Miriam L., Lopez, Priscilla, Davidson, Mikhail, Yee, John

Get full text

Defining Utility Values for Chorea Health States in Patients with Huntington’s Disease by Claassen, Daniel O., Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Leo, Sam, Ribalov, Rinat

“…Introduction Chorea is characterized by sudden, involuntary movements that interfere with quality of life (QOL). Utility values measure preferences for…”
Get full text

116 An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia by Ayyagari, Rajeev, Goldschmidt, Debbie, Mu, Fan, Caroff, Stanley N, Carroll, Benjamin

“…Evaluate the impact of orofacial tardive dyskinesia (TD) symptoms on the professional and social lives of patients with TD. TD, a movement disorder affecting…”
Get full text